Therapeutic Areas 

Global domain expertise across an extensive range of therapeutic areas.

Colorized half circle.
therapeutics consultant-min

Best-in-class project teams

Our teams will be assembled to match the therapeutic requirements for your clinical trials. We focus on providing clinical trial solutions that will deliver your studies with responsiveness, flexibility, and a personalized approach. 

Therapeutic Areas of Focus

Our team of experts has decades of experience across a wide variety of therapeutic areas. We work as an extension of your team, bringing you immediate resources who will align with your processes and environment. By partnering with ProPharma, you can leverage our clinical trial execution capabilities with responsiveness, flexibility, and a personalized approach.

 

Obesity & Diabetes

The obesity drug market is rapidly expanding, fueled by the success of innovative treatments. With an increasing number of pharmaceutical companies, particularly smaller and mid-sized firms, aiming to make an impact in this evolving field, the demand for expertly managed clinical trials is more crucial than ever. ProPharma provides specialized services to guide you through the complexities of obesity clinical trials, ensuring your study not only contributes to scientific advancements but also delivers effective treatments to the patients who need them most.

Oncology

ProPharma has a unique combination of experience across the oncology trial space. We have supported clinical studies across a variety of malignancies in both the pediatric and adult patient populations. Our teams have supported radiolabeled studies and understand the unique complexities and regulations involved with delivering this type of study. Our established site relationships and site network allows our teams to support fast study set up and site activation to meet your most challenging goals.

Explore Oncology CRO Solutions

Cardiovascular

ProPharma’s cardiovascular research team has supported clinical trials across a variety of cardiac diseases in both adult and pediatric patient populations. We understand the challenges that come with delivering this type of study for both drug and medical device and diagnostics.

Cell and Gene Therapy

Our Cell and Gene Therapy Center of Excellence helps clients around the world accelerate their novel, advanced therapeutic products to market. We have cell and gene therapy (CAGT) experts that have supported more than 100 different CAGT development programs.

ProPharma’s CAGT consulting team has a combined 25 years of experience delivering unique lifesaving treatments to market in EU, US, and Japanese regulatory environments. Our diverse talent pool supports you across the full development lifecycle to bring products effectively and efficiently to patients.

CNS (Central Nervous System)

With many unmet needs across a myriad of conditions affecting the central nervous system (CNS), every step forward can have a monumental impact on a patient’s health and everyday activities. Armed with experience in a broad range of indications, we can confidently guide you to your neuroscience discovery.

Infectious Diseases and Vaccines

With the fast pace of infectious disease and vaccine trials, our experienced team knows how to ensure the global scale and intellectual property (IP) logistics are in place to allow for accelerated enrollment. We’ve supported a wide variety of global vaccine trials across adult and patient populations, including COVID-19.

MedTech

ProPharma’s MedTech team knows and understands device and diagnostics regulations, and our staff has experience with the regulatory process for clinical trial and product approval in the US and EU. Our clinical team understands the regulatory implications of its actions and decisions, so you can rest assured your clinical study or regulatory submission is in expert hands.

Explore MedTech

Ophthalmology

Our team understands the unique challenges that ophthalmology clinical trials face, such as requiring special imaging vendors and incorporating cell and gene therapy. Our experts know how to design and execute these types of trials efficiently to help accelerate your path to approval.

Pediatrics

Our multidisciplinary clinical team can create a purposeful strategy to navigate the challenges and risk mitigation strategies associated with pediatric studies. With an awareness of the global pediatric landscape, our team can assist in consent/assent, protocol development, and study design. Our cross-functional teams can support the development process including regulatory strategy, protocol development, execution, and regulatory filing.

Rare / Orphan Diseases

In the rare disease space, patients and their families are faced with a lack of available therapies and huge unmet needs. We understand the challenges these patients endure and reducing their burden is our focus. Our cross-functional team of rare disease experts can leverage in-depth experience to navigate the complexity of developing these therapies while having small patient populations and regulatory obstacles at the forefront of the assigned teams.

Respiratory

We have strong experience in many of the unique aspects that define early clinical research with respiratory and inhaled drug products. We help our customers navigate the complex challenges of respiratory clinical trials through our experienced clinical development team.

News & Insights

A Risk-Based Road Map for Implementing AI

June 22, 2026

A Risk-Based Road Map for Implementing AI

Discover a risk-based approach to implementing AI in life sciences, ensuring compliance, transparency, and governance throughout the entire lifecycle.

Five Metrics That Predict CRO Success (and How to Measure Them)

June 15, 2026

Five Metrics That Predict CRO Success (and How to Measure Them)

Discover five key metrics to evaluate CRO success, ensuring timely clinical trials and data integrity while minimizing costs. Learn how to measure them effectively.

FDA Adds Bemotrizinol to OTC Sunscreen Monograph: What the New GRASE Determination Means for Manufacturers

June 10, 2026

FDA Adds Bemotrizinol to OTC Sunscreen Monograph: What the New GRASE Determinati...

Learn how bemotrizinol achieved GRASE status and what FDA's final order adding the ingredient to the OTC sunscreen monograph means for manufacturers and product development.

ProPharma Welcomes Kevin van Dooren to Strengthen Integrated EU Regulatory and HTA Capabilities

June 18, 2026

ProPharma Welcomes Kevin van Dooren to Strengthen Integrated EU Regulatory and H...

ProPharma welcomes Kevin van Dooren as Vice President, HEOR and Market Access, strengthening integrated EU regulatory, HTA, reimbursement, and market access capabilities for life sciences companies.

ProPharma Appoints Adrian Pencak as Chief Commercial Officer

May 27, 2026

ProPharma Appoints Adrian Pencak as Chief Commercial Officer

ProPharma announces Adrian Pencak as Chief Commercial Officer, bringing 25 years of leadership experience to enhance global commercial capabilities and client partnerships.

ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero Targets

January 27, 2026

ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero T...

ProPharma’s greenhouse gas reduction targets are validated by SBTi, aligning with the Net-Zero Standard and a commitment to reach net-zero by 2050.

ProPharma Recognized for AI Excellence at ECCCSA

January 31, 2025

ProPharma Recognized for AI Excellence at ECCCSA

ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

October 9, 2024

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

September 24, 2024

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

ProPharma honored with Clinical Trials Excellence Award 2024, recognizing their outstanding contributions in the pharmaceutical industry.

Case Study Meeting Patients Where They Are: Delivering Global Clinical Support for Time-Sensitive Research - ProPharma

June 17, 2026

Meeting Patients Where They Are: Delivering Global Clinical Support for Time-Sen...

Conducting clinical research for rare pediatric populations presents unique operational challenges, particularly when eligible patients may be born anywhere in the world and require immediate...

Case Study Accelerating Commercial Readiness for a Novel Cell Therapy Program - ProPharma

June 10, 2026

Accelerating Commercial Readiness for a Novel Cell Therapy Program

As advanced therapy developers move from research-stage operations toward commercialization, they often face significant challenges in scaling quality systems, aligning regulatory strategy, and...

Case Study Keeping Research Moving Under Pressure: Delivering Data Integrity at Speed

May 20, 2026

Keeping Research Moving Under Pressure: Delivering Data Integrity at Speed

When patient enrollment rapidly exceeds expectations, clinical trials can face significant operational strain, putting data integrity, timelines, and critical sponsor decisions at risk. A mid-size...

Foundations of a Compliant EU–UK GMP–GDP Supply Chain: From Importation to Distribution

June 2, 2026

Foundations of a Compliant EU–UK GMP–GDP Supply Chain: From Importation to Distribution

A compliant and efficient EU–UK GMP–GDP supply chain requires a clear understanding of roles, responsibilities, and operational integration across importation, certification, and distribution...

Clinical Promise to Commercial Reality: The Path to Cell & Gene Therapy Market

April 23, 2026

Clinical Promise to Commercial Reality: The Path to Cell & Gene Therapy Market

As cell and gene therapies transition from clinical development to commercialization, organizations face evolving regulatory expectations, expanded CMC requirements, and increased MAH...

EMA Policy 0070: Advanced Strategies for Compliance, Anonymization, and CCI Justification

April 9, 2026

EMA Policy 0070: Advanced Strategies for Compliance, Anonymization, and CCI Justification

As European Medicines Agency Policy 0070 enters its expanded Step 2 phase, sponsors face increased document volumes, heightened transparency obligations, and greater scrutiny of anonymization and CCI...

News & Insights

A Risk-Based Road Map for Implementing AI

June 22, 2026

A Risk-Based Road Map for Implementing AI

Discover a risk-based approach to implementing AI in life sciences, ensuring compliance, transparency, and governance throughout the entire lifecycle.

Five Metrics That Predict CRO Success (and How to Measure Them)

June 15, 2026

Five Metrics That Predict CRO Success (and How to Measure Them)

Discover five key metrics to evaluate CRO success, ensuring timely clinical trials and data integrity while minimizing costs. Learn how to measure them effectively.

FDA Adds Bemotrizinol to OTC Sunscreen Monograph: What the New GRASE Determination Means for Manufacturers

June 10, 2026

FDA Adds Bemotrizinol to OTC Sunscreen Monograph: What the New GRASE Determinati...

Learn how bemotrizinol achieved GRASE status and what FDA's final order adding the ingredient to the OTC sunscreen monograph means for manufacturers and product development.

Previous Post Arrow Next Post Arrow
ProPharma Welcomes Kevin van Dooren to Strengthen Integrated EU Regulatory and HTA Capabilities

June 18, 2026

ProPharma Welcomes Kevin van Dooren to Strengthen Integrated EU Regulatory and H...

ProPharma welcomes Kevin van Dooren as Vice President, HEOR and Market Access, strengthening integrated EU regulatory, HTA, reimbursement, and market access capabilities for life sciences companies.

ProPharma Appoints Adrian Pencak as Chief Commercial Officer

May 27, 2026

ProPharma Appoints Adrian Pencak as Chief Commercial Officer

ProPharma announces Adrian Pencak as Chief Commercial Officer, bringing 25 years of leadership experience to enhance global commercial capabilities and client partnerships.

ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero Targets

January 27, 2026

ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero T...

ProPharma’s greenhouse gas reduction targets are validated by SBTi, aligning with the Net-Zero Standard and a commitment to reach net-zero by 2050.

Previous Post Arrow Next Post Arrow
ProPharma Recognized for AI Excellence at ECCCSA

January 31, 2025

ProPharma Recognized for AI Excellence at ECCCSA

ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

October 9, 2024

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

September 24, 2024

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

ProPharma honored with Clinical Trials Excellence Award 2024, recognizing their outstanding contributions in the pharmaceutical industry.

Previous Award Arrow Next Award Arrow
Case Study Meeting Patients Where They Are: Delivering Global Clinical Support for Time-Sensitive Research - ProPharma

June 17, 2026

Meeting Patients Where They Are: Delivering Global Clinical Support for Time-Sen...

Conducting clinical research for rare pediatric populations presents unique operational challenges, particularly when eligible patients may be born anywhere in the world and require immediate...

Case Study Accelerating Commercial Readiness for a Novel Cell Therapy Program - ProPharma

June 10, 2026

Accelerating Commercial Readiness for a Novel Cell Therapy Program

As advanced therapy developers move from research-stage operations toward commercialization, they often face significant challenges in scaling quality systems, aligning regulatory strategy, and...

Case Study Keeping Research Moving Under Pressure: Delivering Data Integrity at Speed

May 20, 2026

Keeping Research Moving Under Pressure: Delivering Data Integrity at Speed

When patient enrollment rapidly exceeds expectations, clinical trials can face significant operational strain, putting data integrity, timelines, and critical sponsor decisions at risk. A mid-size...

Previous Resource Arrow Next Resource Arrow
Foundations of a Compliant EU–UK GMP–GDP Supply Chain: From Importation to Distribution

June 2, 2026

Foundations of a Compliant EU–UK GMP–GDP Supply Chain: From Importation to Distribution

A compliant and efficient EU–UK GMP–GDP supply chain requires a clear understanding of roles, responsibilities, and operational integration across importation, certification, and distribution...

Clinical Promise to Commercial Reality: The Path to Cell & Gene Therapy Market

April 23, 2026

Clinical Promise to Commercial Reality: The Path to Cell & Gene Therapy Market

As cell and gene therapies transition from clinical development to commercialization, organizations face evolving regulatory expectations, expanded CMC requirements, and increased MAH...

EMA Policy 0070: Advanced Strategies for Compliance, Anonymization, and CCI Justification

April 9, 2026

EMA Policy 0070: Advanced Strategies for Compliance, Anonymization, and CCI Justification

As European Medicines Agency Policy 0070 enters its expanded Step 2 phase, sponsors face increased document volumes, heightened transparency obligations, and greater scrutiny of anonymization and CCI...

Previous Webinar Arrow Next Webinar Arrow

Where Personalized Approach Meets Therapeutic Expertise

Meeting the demands of complex therapeutic areas requires expert guidance and a collaborative approach. With global reach and deep industry expertise, we provide personalized solutions and strategic insights, ensuring alignment with your goals every step of the way.